AL002

TargetTREM2

Modalitymonoclonal antibody (TREM2 agonist)

IndicationAlzheimer's disease

PhasePhase 2 (Discontinued)

PartnerAbbVie

Trial IDNCT04592874

Notes

INVOKE-2 trial. AL002 was an anti-TREM2 agonist antibody designed to enhance TREM2 signaling in microglia. The program was discontinued after failing to meet its primary efficacy endpoint (CDR-SB) and secondary endpoints in Phase 2.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 2, 2026